2016
Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models
Marek E, Momper J, Hines R, Takao C, Gill J, Pravica V, Gaedigk A, Burckart G, Neville K. Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. The Journal Of Pediatric Pharmacology And Therapeutics 2016, 21: 224-32. PMID: 27453700, PMCID: PMC4956330, DOI: 10.5863/1551-6776-21.3.224.Peer-Reviewed Original ResearchValidation cohortPediatric patientsStable international normalized ratioInternational normalized ratioStable warfarin dosesFixed-dose approachActual maintenance doseMaintenance doseMaintenance dosesStandard careMulticenter trialWarfarin dosesNormalized ratioSeparate clinical sitesWarfarin doseIndependent cohortClinical sitesCohortPatientsDose prediction modelDose modelDosesProportion of varianceObserved dosesDose
2010
Pharmacogenetic Testing in the Pediatric Epileptic Population
Sander T, Marcuccilli C, Zembles T, Hines R, Lo S, North P. Pharmacogenetic Testing in the Pediatric Epileptic Population. The FASEB Journal 2010, 24: 568.16-568.16. DOI: 10.1096/fasebj.24.1_supplement.568.16.Peer-Reviewed Original ResearchAdverse drug reactionsAntiepileptic drugsSevere adverse drug reactionsABCB1 genetic variantsChronic neurologic disordersFast Real-Time PCR SystemRecurrent unprovoked seizuresAED therapyPediatric patientsUnprovoked seizuresADR riskDrug reactionsPhysician comfortNeurologic disordersEpileptic populationPharmacogenetic testingTherapeutic windowPharmacogenetic testsPatientsTherapeutic treatmentGenotype resultsReal-time PCR systemGenotyping assaysTherapyGenetic variants
2002
GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO)
Krueger S, Williams D, Yueh M, Martin S, Hines R, Raucy J, Dolphin C, Shephard E, Phillips I. GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO). Drug Metabolism Reviews 2002, 34: 523-532. PMID: 12214664, DOI: 10.1081/dmr-120005653.Peer-Reviewed Original ResearchConceptsFlavin-Containing MonooxygenaseAdult human liverPercent of individualsPlethora of drugsTrimethylamine N-oxygenationDrug metabolismHuman liverGenetic polymorphismsHispanic descentPremature stop codonPolymorphic expressionLungPreliminary evidenceFunctional FMO2African descentXenobiotic toxicityMammalian flavinN-oxygenationFMO2TrimethylaminuriaEthylene thioureaPolymorphismAllelesPatientsExpression
1990
Expression of CYP1A1 Gene in Patients With Lung Cancer: Evidence for Cigarette Smoke-Induced Gene Expression in Normal Lung Tissue and for Altered Gene Regulation in Primary Pulmonary Carcinomas
McLemore T, Adelberg S, Liu M, McMahon N, Yu S, Hubbard W, Czerwinski M, Wood T, Storeng R, Lubet R, Eggleston J, Boyd M, Hines R. Expression of CYP1A1 Gene in Patients With Lung Cancer: Evidence for Cigarette Smoke-Induced Gene Expression in Normal Lung Tissue and for Altered Gene Regulation in Primary Pulmonary Carcinomas. Journal Of The National Cancer Institute 1990, 82: 1333-1339. PMID: 2380990, DOI: 10.1093/jnci/82.16.1333.Peer-Reviewed Original ResearchConceptsNormal lung tissuesLung tissueLung cancerFormer smokersCigarette smokersCYP1A1 gene expressionCYP1A1 geneActive cigarette smokersPrimary pulmonary carcinomasHuman pulmonary tissueMessenger RNA expressionPulmonary carcinogenesisCigarette smokingPulmonary carcinomaTime-dependent decreasePulmonary tissueGene expressionSmokersCarcinoma tissuesPatientsCancerTumorsRNA expressionMRNA levelsCYP1A1 mRNA